Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
IGF-1 LR3 (LR3) is a muscle peptide, at the research chemical stage in the published literature. Long-acting analog of IGF-1 with extended half-life due to amino acid substitutions. Potent anabolic peptide for muscle growth.
Long-acting analog of IGF-1 with extended half-life due to amino acid substitutions. Potent anabolic peptide for muscle growth.
| Research Status | Research chemical |
|---|---|
| Half-Life | 20-30 hours |
| Administration | Subcutaneous or intramuscular |
| Doses Reported in Published Studies | 20-100 mcg |
Binds IGF-1 receptor with reduced affinity for binding proteins, increasing bioavailability and half-life.
Long-acting analog of IGF-1 with extended half-life due to amino acid substitutions. Potent anabolic peptide for muscle growth.
Binds IGF-1 receptor with reduced affinity for binding proteins, increasing bioavailability and half-life.
IGF-1 LR3 is at the following stage in the published literature: Research chemical. All information is for research and educational purposes only.
Reported half-life: 20-30 hours.
Reported administration route in the literature: Subcutaneous or intramuscular. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.